Arcadia Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.9M | $5.0M | $4.5M | $7.4M | $6.8M |
| Operating income | -$2.5M | -$3.6M | -$6.1M | -$14.0M | -$35.5M |
| Cost of revenue | $3.1M | $3.0M | $2.2M | $6.1M | $8.7M |
| Cash from operations | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$25.9M |
| Capital expenditure | $0 | $16,000 | $5,000 | $72,000 | $1.0M |
| Free cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$26.9M |
| Impairments | $0 | $36,000 | $0 | $160,000 | $1.4M |
| Total assets | $6.5M | $13.5M | $19.7M | $28.9M | $43.9M |
| Total liabilities | $2.4M | $7.3M | $7.0M | $8.0M | $12.7M |
Shares outstanding 2.1M · Free float 99.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.